Editorial: Nitroglycerin-mediated S-nitrosylation of proteins: A field comes full cycle

Circulation Research

Volumn 103, Issue 6, 2008, Pages 557-559

  Stamler, Joathan S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Guanylate cyclase; Nitroglycerin; S nitrosylation; Tolerance

Indexed keywords

ACETYLCHOLINE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEMOGLOBIN; NITRIC OXIDE; S NITROSOCYSTEINE; S NITROSOTHIOL; NITROSO DERIVATIVE; PROTEIN;

ANGINA PECTORIS; CHEMICAL MODIFICATION; DRUG MECHANISM; EDITORIAL; ERYTHROCYTE; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HUMAN; MICROCIRCULATION; NITROSYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; TACHYPHYLAXIS; TREATMENT RESPONSE; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION; VENOUS CIRCULATION; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECT; METABOLISM; NOTE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MICROCIRCULATION; NITROGLYCERIN; NITROSO COMPOUNDS; PROTEINS;

EID: 53249119775     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.184341     Document Type: Editorial

References (34)

1. Gersh BJ, Braunwald E, Rutherford JD. Chronic coronary artery disese. In: Braunwald E, Zipes DP, Libby P, Bonow R, eds. Braunwald'ss Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: Saunders; 1997:302-1304.
2. Bin JP, Doctor A, Lindner J, Hendersen EM, Le DE, Leong-Poi H, Fisher NG, Christiansen J, Kaul S. Effects of nitroglycerin on erythrocyte rheology and oxygen unloading: novel role of S-nitrosohemoglobin in relieving myocardial ischemia. Circulation. 2006;113:2502-2508.
3. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitro-glycerin. Circulation. 1991;84:2336-2345.
4. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Keaney JF Jr, Stamler JS, Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113: 482-489.
5. Forster S, Woditsch I, Schroder H, Schror K. Reduced nitric oxide release causes nitrate tolerance in the intact coronary circulation. J Cardiovasc Pharmacol. 1991;17:867-872.
6. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
7. Sayed N, Baskaran P, Ma X, van den Akker F, Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A. 2007;104:12312-12317. (Pubitemid 47206134)
8. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Durán WN, Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res. 2008;103: 606-614.
9. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452:646-649.
10. Stamler JS, Sun QA, Hess DT. A SNO storm in skeletal muscle. Cell. 2008;133:33-35.
11. Nielsen TT, Sorensen KE. [Discovery of "endogenous nitroglycerin", NO, as cellular signal molecule]. Ugeskr Laeger. 1998;160:7567.
12. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med. 2003;9:160-168.
13. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, McMahon TJ, Dickfeld T, Marshall HE, Que LG, Stamler JS. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell. 2004; 116:617-628.
14. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850-853.
15. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485.
16. Sellke FW, Myers PR, Bates JN, Harrison DG. Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. Am J Physiol. 1990;258:H515-H520.
17. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary micro-vascular response to nitroglycerin. Circ Res. 1991;68:847-855.
18. Sellke FW, Tomanek RJ, Harrison DG. L-cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharmacol Exp Ther. 1991;258:365-369.
19. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
20. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
21. Diesen DL, Hess DT, Stamler JS. Hypoxic vasodilation by red blood cells. Evidence for an S-nitrosothiol-based signal. Circ Res. 2008;103.
22. Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T, Gaston B. S-nitrosothiols signal hypox-ia-mimetic vascular pathology. J Clin Invest. 2007;117:2592-2601.
23. Nunez C, Victor VM, Tur R, Alvarez-Barrientos A, Moncada S, Esplugues JV, D'sOcon P. Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circ Res. 2005;97:1063-1069.
24. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, Kitagawa K, Nakayama KI, Hess DT, Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159-12164.
25. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99: 8306-8311.
26. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles. Br J Pharmacol. In press.
27. Moon KH, Kim BJ, Song BJ. Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett. 2005; 579:6115-6120.
28. Murphy TC, Arntzen R, Picklo MJ Sr. Nitrate-based vasodilators inhibit multiple vascular aldehyde dehydrogenases. Cardiovasc Toxicol. 2005;5: 321-332.
29. Towell J, Garthwaite T, Wang R. Erythrocyte aldehyde dehydrogenase and disulfiram-like side effects of hypoglycemics and antianginals. Alcohol Clin Exp Res. 1985;9:438-442.
30. Esplugues JV, Rocha M, Nunez C, Bosca I, Ibiza S, Herance JR, Ortega A, Serrador JM, D'sOcon P, Victor VM. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res. 2006;99:1067-1075.
31. Li Y, Zhang D, Jin W, Shao C, Yan P, Xu C, Sheng H, Liu Y, Yu J, Xie Y, Zhao Y, Lu D, Nebert DW, Harrison DC, Huang W, Jin L. Mito-chondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglyc-erin. J Clin Invest. 2006;116:506-511.
32. Mackenzie IS, Maki-Petaja KM, McEniery CM, Bao YP, Wallace SM, Cheriyan J, Monteith S, Brown MJ, Wilkinson IB. Aldehyde dehydro-genase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005;25:1891-1895.
33. Huellner MW, Schrepfer S, Weyand M, Weiner H, Wimplinger I, Eschenhagen T, Rau T. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins. FASEB J. 2008;22:2561-2568.
34. Zhang J, Chen Z, Cobb FR, Stamler JS. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation. 2004;110: 750-755.